[go: up one dir, main page]

BRPI0916232A2 - Moduladores do receptor de esfingosina-1-fosfato e seu uso para tratar inflamação muscular - Google Patents

Moduladores do receptor de esfingosina-1-fosfato e seu uso para tratar inflamação muscular

Info

Publication number
BRPI0916232A2
BRPI0916232A2 BRPI0916232A BRPI0916232A BRPI0916232A2 BR PI0916232 A2 BRPI0916232 A2 BR PI0916232A2 BR PI0916232 A BRPI0916232 A BR PI0916232A BR PI0916232 A BRPI0916232 A BR PI0916232A BR PI0916232 A2 BRPI0916232 A2 BR PI0916232A2
Authority
BR
Brazil
Prior art keywords
sphingosine
receptor modulators
phosphate receptor
muscle inflammation
treat muscle
Prior art date
Application number
BRPI0916232A
Other languages
English (en)
Inventor
Gergely Peter
Sohail Ahmed Syed
Londei Marco
Wright Timothy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40090418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0916232(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0916232A2 publication Critical patent/BRPI0916232A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

MODULADORES DO RECEPTOR DE ESFINGOSINA-1-FOSFATO E SEU USO PARA TRATAR INFLAMAÇÃO MUSCULAR. A presente invenção refere-se a uso de um modulador do receptor de S1P da fórmula Ia ou IB, em que o significado dos diferentes resíduos é aquele indicado na reivindicação 1, para preparar um medicamento destinado a prevenir, inibir ou tratar uma condição inflamatória selecionada a partir de polimiosite, dermatomiosite e doenças neuromusculares, por exemplo, distrofias musculares e miosite por corpos de inclusão.
BRPI0916232A 2008-07-23 2009-07-22 Moduladores do receptor de esfingosina-1-fosfato e seu uso para tratar inflamação muscular BRPI0916232A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161005 2008-07-23
PCT/EP2009/059440 WO2010010127A1 (en) 2008-07-23 2009-07-22 Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation

Publications (1)

Publication Number Publication Date
BRPI0916232A2 true BRPI0916232A2 (pt) 2017-08-29

Family

ID=40090418

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916232A BRPI0916232A2 (pt) 2008-07-23 2009-07-22 Moduladores do receptor de esfingosina-1-fosfato e seu uso para tratar inflamação muscular

Country Status (24)

Country Link
US (2) US9149459B2 (pt)
EP (2) EP2695615A3 (pt)
JP (2) JP5878015B2 (pt)
KR (2) KR101624098B1 (pt)
CN (1) CN102105144B (pt)
AU (1) AU2009273259B2 (pt)
BR (1) BRPI0916232A2 (pt)
CA (1) CA2730751A1 (pt)
CL (1) CL2011000138A1 (pt)
CY (1) CY1115662T1 (pt)
DK (1) DK2307007T3 (pt)
ES (1) ES2522345T3 (pt)
HR (1) HRP20141152T1 (pt)
IL (2) IL210550A (pt)
MA (1) MA32557B1 (pt)
MX (1) MX2011000881A (pt)
NZ (1) NZ590328A (pt)
PL (1) PL2307007T3 (pt)
PT (1) PT2307007E (pt)
RU (1) RU2521286C2 (pt)
SG (1) SG10201503157PA (pt)
SI (1) SI2307007T1 (pt)
WO (1) WO2010010127A1 (pt)
ZA (1) ZA201100166B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2326325B1 (en) * 2008-08-18 2014-11-12 Novartis AG Azetidine derivative for the treatment of peripheral neuropathies
MA34897B1 (fr) 2011-01-07 2014-02-01 Novartis Ag Formulations d'immunosupresseurs
WO2012097330A2 (en) * 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
FR3000959B1 (fr) 2013-01-14 2015-08-21 Holis Technologies Nouveaux intermediaires de synthese permettant d'acceder avec de bons rendements a des derives de sphingosines, ceramides et sphingomyelines
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US11061017B2 (en) 2015-06-18 2021-07-13 Cytoo High throughput and functional screening method for muscle related disorders and biological processes
WO2017120124A1 (en) 2016-01-04 2017-07-13 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
CN115884762B (zh) * 2020-08-20 2025-12-05 南京明德新药研发有限公司 苯乙酮肟类化合物及其应用
CN119776509A (zh) * 2023-10-08 2025-04-08 华东师范大学 Ndufa10基因和S1pr4基因突变在肌病诊断、预测和治疗中的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0749419B1 (de) * 1994-03-10 2001-10-24 Bayer Ag Oxim-derivate und ihre verwendung als schädlingsbekämpfungsmittel
AR035411A1 (es) * 2000-12-29 2004-05-26 Fujisawa Pharmaceutical Co Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto
US20050043534A1 (en) * 2001-07-11 2005-02-24 Alicja Bielawska Modulators of ceramidase and methods of used based thereon
US20050070506A1 (en) * 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
TW200424187A (en) 2003-04-04 2004-11-16 Hoffmann La Roche New oxime derivatives and their use as pharmaceutically active agents
AR044402A1 (es) 2003-05-19 2005-09-14 Irm Llc Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
US7462629B2 (en) * 2003-05-19 2008-12-09 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
JP2007522181A (ja) * 2004-02-16 2007-08-09 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ シクロオキシゲナーゼ−１及びシクロオキシゲナーゼ−２阻害剤としての置換アゼチジン化合物、ならびにそれらの調製、および薬剤としての使用
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
EP1804793A4 (en) * 2004-10-22 2010-03-31 Merck Sharp & Dohme 2- (ARYL) AZACYCLYLMETHYL-CARBOXYLATE, SULPHONATE, PHOSPHONATE, PHOSPHINATE AND HETEROCYCLES AS S1P RECEPTOR AGONISTS
ES2495690T3 (es) * 2004-11-29 2014-09-17 Novartis Ag Régimen de dosificación de un agonista del receptor S1P
US7919519B2 (en) 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
ES2393631T3 (es) * 2006-08-17 2012-12-26 University Of Chicago Tratamiento de enfermedades inflamatorias
CN101522645B (zh) * 2006-09-21 2013-01-09 埃科特莱茵药品有限公司 苯衍生物及其免疫调节剂的用途
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
NZ579595A (en) 2007-04-19 2012-06-29 Glaxo Group Ltd Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists
TW200920355A (en) 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
AR074825A1 (es) * 2008-12-22 2011-02-16 Novartis Ag Regimen de dosificacion de un agonista de los receptores de s1p, metodo de tratamiento y kit

Also Published As

Publication number Publication date
RU2011106356A (ru) 2012-08-27
KR101624098B1 (ko) 2016-05-24
US20160175282A1 (en) 2016-06-23
CN102105144A (zh) 2011-06-22
DK2307007T3 (da) 2014-11-10
EP2307007A1 (en) 2011-04-13
HRP20141152T1 (hr) 2015-01-16
IL210550A0 (en) 2011-03-31
KR101608108B1 (ko) 2016-03-31
ES2522345T3 (es) 2014-11-14
JP2011528695A (ja) 2011-11-24
MX2011000881A (es) 2011-03-02
RU2521286C2 (ru) 2014-06-27
WO2010010127A1 (en) 2010-01-28
CL2011000138A1 (es) 2011-07-01
SI2307007T1 (sl) 2014-11-28
KR20160039694A (ko) 2016-04-11
JP2015038100A (ja) 2015-02-26
CA2730751A1 (en) 2010-01-28
KR20110031996A (ko) 2011-03-29
IL210550A (en) 2016-02-29
MA32557B1 (fr) 2011-08-01
EP2307007B1 (en) 2014-08-27
SG10201503157PA (en) 2015-06-29
PT2307007E (pt) 2014-11-13
AU2009273259B2 (en) 2013-05-02
EP2695615A2 (en) 2014-02-12
HK1155096A1 (en) 2012-05-11
US9149459B2 (en) 2015-10-06
EP2695615A3 (en) 2014-04-30
IL243612A0 (en) 2016-02-29
JP5878015B2 (ja) 2016-03-08
US20110124620A1 (en) 2011-05-26
NZ590328A (en) 2013-04-26
PL2307007T3 (pl) 2015-03-31
AU2009273259A1 (en) 2010-01-28
CY1115662T1 (el) 2017-01-25
ZA201100166B (en) 2011-09-28
CN102105144B (zh) 2013-11-13

Similar Documents

Publication Publication Date Title
BRPI0916232A2 (pt) Moduladores do receptor de esfingosina-1-fosfato e seu uso para tratar inflamação muscular
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
BR112014010291A2 (pt) composições de lipossoma combinacionais para terapia de câncer
BR112012010705A2 (pt) composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio
BRPI0514316A (pt) métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)
BRPI0719092B8 (pt) compostos do tipo tetra-hidrociclopen-ta[b]indol, seus usos, e composição farmacêutica
BRPI0714904A8 (pt) composições contendo cdp-colina, e seus métodos de uso
BR122019016628B8 (pt) uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
BR112013023803A2 (pt) dispositivo para inervação magnética extracorpórea
BR112015014592A2 (pt) composto, composição farmacêutica, e, método para o tratamento de um humano
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BR112015003796A2 (pt) composição ansiolítica, formulação e método de uso
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
BR112012018256A8 (pt) método de tratamento de doença de parkinson
BR112012031580A2 (pt) derivado de tetra-hidrocarbolina
BR112012005044B8 (pt) composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib
BR112014019399A2 (pt) métodos de tratamento da fibrose
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BR112013031117A8 (pt) Scilo-inositol para o tratamento de transtornos comportamentais e psiquiátricos.
BR112012024114A2 (pt) derivados de 3- (heteroarilamino)-1,2,3,4- tetrahidro-9h-carbazol e o seu uso como moduladores do receptor de prostaglandina d2.
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
MX2013000694A (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.